Dosing referencenever gated · no calculator
What the label or the trial says.
Per peptide, the figure the drug label or the published trial gives, with the source beside it. Under many rows, the full protocols on file — starting dose, escalation, target, cycle — each badged FDA label, clinical trial or community protocol, and each linked to where it came from. Where there is nothing to cite, the row says so.
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
Peptide · gradeWhat the label or trial saysSource
5-Amino-1MQgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily
Start: 50 mg oral once daily, weeks 1-2. SC: 2.5 mg daily on days 1-2, then 5 mg.
Then: 100 mg oral daily from week 3; 150 mg is the upper option
Target: 50-150 mg/day oral; 2.5-5 mg/day SC
Cycle: 8 to 12 weeks on, then 4 to 6 weeks off
Start: 50 mg oral once daily, weeks 1-2. SC: 2.5 mg daily on days 1-2, then 5 mg.
Then: 100 mg oral daily from week 3; 150 mg is the upper option
Target: 50-150 mg/day oral; 2.5-5 mg/day SC
Cycle: 8 to 12 weeks on, then 4 to 6 weeks off
AOD-9604grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialPhase 2b, oral (Metabolic Pharmaceuticals, reported 2004)
Once daily, 12 weeks
Start: Fixed arms; no escalation
Then: None
Target: Arms: 1, 5, 10, 20 or 30 mg. 1 mg did best: -2.8 kg vs -0.8 kg on placebo; higher doses were not better.
Start: Fixed arms; no escalation
Then: None
Target: Arms: 1, 5, 10, 20 or 30 mg. 1 mg did best: -2.8 kg vs -0.8 kg on placebo; higher doses were not better.
Community protocol — not clinically establishedCommunity guide
Once daily, preferably in the morning on an empty stomach
Start: 300 mcg SC once daily, weeks 1-4
Then: 500 mcg once daily, weeks 5-12
Target: 300-500 mcg/day SC
Cycle: 12 weeks (guides quote 8 to 20)
Start: 300 mcg SC once daily, weeks 1-4
Then: 500 mcg once daily, weeks 5-12
Target: 300-500 mcg/day SC
Cycle: 12 weeks (guides quote 8 to 20)
ARA-290grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 3 · trial / community
Clinical trialPhase 2, type 2 diabetes with neuropathy (Brines 2014)
Once daily, 28 days
Start: 4 mg SC daily
Then: None
Target: 4 mg SC daily for 28 days
Start: 4 mg SC daily
Then: None
Target: 4 mg SC daily for 28 days
Clinical trialPhase 2b, sarcoidosis small-fibre neuropathy
Once daily, 28 days
Start: Arms: 1, 4 or 8 mg SC daily
Then: None
Target: 1, 4 or 8 mg SC daily for 28 days
Start: Arms: 1, 4 or 8 mg SC daily
Then: None
Target: 1, 4 or 8 mg SC daily for 28 days
Community protocol — not clinically establishedCommunity guide
Once daily
Start: 1-4 mg/day
Then: "Up to 8 mg/day (trial ceiling)"
Target: 4 mg once daily
Cycle: "About 4 weeks, matching trial blocks"
Start: 1-4 mg/day
Then: "Up to 8 mg/day (trial ceiling)"
Target: 4 mg once daily
Cycle: "About 4 weeks, matching trial blocks"
BPC-157grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 4 · trial / community
Clinical trialIV safety pilot (2025, n=2)
Two infusions on consecutive days
Start: 10 mg IV, day 1
Then: 20 mg IV, day 2
Target: Not a treatment regimen; no adverse effects on measured biomarkers
Start: 10 mg IV, day 1
Then: 20 mg IV, day 2
Target: Not a treatment regimen; no adverse effects on measured biomarkers
SourcePubMed 40131143 ↗
Clinical trialInterstitial cystitis pilot (2024, n=12, uncontrolled)
Single procedure
Start: 10 mg total, 1 mg at each of 10 bladder sites
Then: None
Target: Single procedure
Start: 10 mg total, 1 mg at each of 10 bladder sites
Then: None
Target: Single procedure
SourceUroToday abstract ↗
Community protocol — not clinically establishedCommunity guide — injectable
Once or twice daily
Start: About 250 mcg once daily (low tier)
Then: Standard about 250 mcg twice daily; high about 500 mcg twice daily "for acute-injury models"
Target: About 250 mcg twice daily, "the most common research-planning band"
Cycle: 4-6 weeks standard; 6-8 or 8-12 weeks for slow-remodelling tissue; 2-4 weeks off between cycles
Start: About 250 mcg once daily (low tier)
Then: Standard about 250 mcg twice daily; high about 500 mcg twice daily "for acute-injury models"
Target: About 250 mcg twice daily, "the most common research-planning band"
Cycle: 4-6 weeks standard; 6-8 or 8-12 weeks for slow-remodelling tissue; 2-4 weeks off between cycles
Community protocol — not clinically establishedCommunity guide — oral
Once or twice daily
Start: Not separately stated
Then: Not stated
Target: "~250-500 mcg once or twice daily"
Start: Not separately stated
Then: Not stated
Target: "~250-500 mcg once or twice daily"
CJC-1295 (no DAC)grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide — no DAC (Mod GRF 1-29)
Once daily (pre-bed) most common; 1-2x daily in the "advanced" phase
Start: 100 mcg once daily, weeks 1-2
Then: 150 mcg once daily weeks 3-4 ("Increase by 50 mcg only if initiation is tolerated")
Target: 200 mcg once daily, weeks 5-8 ("common maintenance level"); advanced 200-300 mcg 1-2x daily
Cycle: Standard 8-12 weeks on / 4-6 weeks off; short 4-6 weeks on / 2-4 weeks off
Start: 100 mcg once daily, weeks 1-2
Then: 150 mcg once daily weeks 3-4 ("Increase by 50 mcg only if initiation is tolerated")
Target: 200 mcg once daily, weeks 5-8 ("common maintenance level"); advanced 200-300 mcg 1-2x daily
Cycle: Standard 8-12 weeks on / 4-6 weeks off; short 4-6 weeks on / 2-4 weeks off
CJC-1295 + Ipamorelingrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily at bedtime, fasted
Start: Not separately specified
Then: Not separately specified; follows the component protocols
Target: 100 mcg CJC-1295 no DAC (Mod GRF 1-29) + 200 mcg ipamorelin in one SC bedtime shot
Cycle: Not separately specified. Component cycles are 8-12 weeks on / 4 weeks off (ipamorelin) and 8-12 on / 4-6 off (CJC no DAC).
Start: Not separately specified
Then: Not separately specified; follows the component protocols
Target: 100 mcg CJC-1295 no DAC (Mod GRF 1-29) + 200 mcg ipamorelin in one SC bedtime shot
Cycle: Not separately specified. Component cycles are 8-12 weeks on / 4 weeks off (ipamorelin) and 8-12 on / 4-6 off (CJC no DAC).
CJC-1295 with DACgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialSingle-dose study in healthy adults (Teichman, JCEM 2006)
Single dose
Start: Single SC doses of 30, 60 or 125 mcg/kg
Then: None
Target: Not a therapeutic regimen. 60 mcg/kg gave about 2-fold GH elevation for 6 days; best tolerated at 30 or 60 mcg/kg.
Start: Single SC doses of 30, 60 or 125 mcg/kg
Then: None
Target: Not a therapeutic regimen. 60 mcg/kg gave about 2-fold GH elevation for 6 days; best tolerated at 30 or 60 mcg/kg.
SourcePubMed 16352683 ↗
Community protocol — not clinically establishedCommunity guide
Once weekly (or split twice weekly)
Start: 500-1,000 mcg once weekly, weeks 1-2
Then: To 1,000 mcg/week weeks 3-8; "elevated" 2,000 mcg/week or 1 mg twice weekly, weeks 3-12
Target: 1,000 mcg (1 mg) once weekly ("most common maintenance dose")
Cycle: Standard 8-12 weeks on / 4-6 weeks off; extended 12-16 weeks on / 6-8 weeks off
Start: 500-1,000 mcg once weekly, weeks 1-2
Then: To 1,000 mcg/week weeks 3-8; "elevated" 2,000 mcg/week or 1 mg twice weekly, weeks 3-12
Target: 1,000 mcg (1 mg) once weekly ("most common maintenance dose")
Cycle: Standard 8-12 weeks on / 4-6 weeks off; extended 12-16 weeks on / 6-8 weeks off
DSIPgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialChronic insomnia (Schneider-Helmert, 1981, n=6)
Acute
Start: 25 nmol/kg IV
Then: None
Target: Acute dose; longer, less-interrupted sleep, no daytime sedation
Start: 25 nmol/kg IV
Then: None
Target: Acute dose; longer, less-interrupted sleep, no daytime sedation
SourcesPubMed 7028502 ↗ · PubMed 3583493 (1987) ↗
Community protocol — not clinically establishedCommunity guide
Once, in the evening, 1-3 hours before intended sleep
Start: 100-200 mcg SC ("most common community range"); no formal escalation
Then: None. Higher tier 200-300 mcg "used in some research write-ups".
Target: 100-300 mcg SC evening
Cycle: Short 5-7 nights; standard 4 weeks; extended 6-8 weeks
Start: 100-200 mcg SC ("most common community range"); no formal escalation
Then: None. Higher tier 200-300 mcg "used in some research write-ups".
Target: 100-300 mcg SC evening
Cycle: Short 5-7 nights; standard 4 weeks; extended 6-8 weeks
Epitalon / Epithalongrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Daily during a short course, evening
Start: No titration; two patterns
Then: None
Target: Pattern 1: 5 mg/day SC x 20 days. Pattern 2: 10 mg/day SC x 10 days. About 100 mg per course either way.
Cycle: 10-20 days on; 4-6 months off; 2-3 courses/year
Start: No titration; two patterns
Then: None
Target: Pattern 1: 5 mg/day SC x 20 days. Pattern 2: 10 mg/day SC x 10 days. About 100 mg per course either way.
Cycle: 10-20 days on; 4-6 months off; 2-3 courses/year
GHRP-2grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedVendor guide
2-3x daily
Start: Not separately specified
Then: None described
Target: "100 mcg per injection, 2 to 3 times per day" (200-300 mcg/day)
Start: Not separately specified
Then: None described
Target: "100 mcg per injection, 2 to 3 times per day" (200-300 mcg/day)
GHRP-6grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialMechanistic study in healthy men (Pandya, JCEM 1998)
Single bolus
Start: 1 mcg/kg IV
Then: None
Target: Mechanistic study, not a regimen
Start: 1 mcg/kg IV
Then: None
Target: Mechanistic study, not a regimen
SourcePubMed 9543138 ↗
Community protocol — not clinically establishedCommunity guide
3x daily, at least 4 h apart
Start: 100 mcg per injection, weeks 1-2
Then: 200 mcg weeks 3-4
Target: 300 mcg per injection, weeks 5-12, 3x daily ("the saturation point")
Cycle: "Several weeks to a few months"; planning examples 4-12 weeks
Start: 100 mcg per injection, weeks 1-2
Then: 200 mcg weeks 3-4
Target: 300 mcg per injection, weeks 5-12, 3x daily ("the saturation point")
Cycle: "Several weeks to a few months"; planning examples 4-12 weeks
GLOWgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily
Start: 10 units once daily (about 2.33 mg blend)
Then: Not stated
Target: 10 units daily. Separate-vial equivalent: BPC-157 250-500 mcg daily, TB-500 2.5-5 mg twice weekly, GHK-Cu 1-2 mg daily.
Cycle: 4-6 weeks on, 2-4 weeks off
Start: 10 units once daily (about 2.33 mg blend)
Then: Not stated
Target: 10 units daily. Separate-vial equivalent: BPC-157 250-500 mcg daily, TB-500 2.5-5 mg twice weekly, GHK-Cu 1-2 mg daily.
Cycle: 4-6 weeks on, 2-4 weeks off
Hexarelingrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialDose-response in healthy men (acute GH stimulation)
Single bolus
Start: IV boluses of 0.5, 1 and 2 mcg/kg
Then: None
Target: GH plateau at about 1.0 mcg/kg; ED50 0.48 mcg/kg
Start: IV boluses of 0.5, 1 and 2 mcg/kg
Then: None
Target: GH plateau at about 1.0 mcg/kg; ED50 0.48 mcg/kg
SourcesPubMed 7957536 ↗ · JCEM 1994;78(3):693 ↗
Community protocol — not clinically establishedVendor guide
1-2x daily
Start: Not separately specified
Then: None described
Target: "1 to 2 mcg/kg per injection", 1-2x daily
Cycle: "4 to 8 weeks on, followed by an off period of equal length"
Start: Not separately specified
Then: None described
Target: "1 to 2 mcg/kg per injection", 1-2x daily
Cycle: "4 to 8 weeks on, followed by an off period of equal length"
IGF-1 LR3grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily
Start: 20 mcg/day ("used to gauge tolerance and hypoglycemic response")
Then: Low 20-40 mcg/day; moderate 40-80; high 80-100 mcg/day
Target: 40-60 mcg/day; "diminishing returns commonly reported above ~50-60 mcg/day"
Cycle: Standard 4 weeks on / 4 off minimum; "Continuous, multi-month use is widely discouraged"
Start: 20 mcg/day ("used to gauge tolerance and hypoglycemic response")
Then: Low 20-40 mcg/day; moderate 40-80; high 80-100 mcg/day
Target: 40-60 mcg/day; "diminishing returns commonly reported above ~50-60 mcg/day"
Cycle: Standard 4 weeks on / 4 off minimum; "Continuous, multi-month use is widely discouraged"
Ipamorelingrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialPhase 2, postoperative ileus (Beck, Int J Colorectal Dis 2014)
Twice daily, postoperative day 1-7 or discharge
Start: 0.03 mg/kg IV
Then: None
Target: 0.03 mg/kg IV twice daily. Well tolerated; no significant efficacy difference vs placebo.
Start: 0.03 mg/kg IV
Then: None
Target: 0.03 mg/kg IV twice daily. Well tolerated; no significant efficacy difference vs placebo.
Community protocol — not clinically establishedCommunity guide
1-3x daily
Start: 100 mcg once daily at bedtime, fasted, about week 1
Then: 200 mcg weeks 2-3 (1x or split 2x)
Target: 200-300 mcg/day, 1-2x daily, weeks 4-8. Per-shot ceiling 100-300 mcg.
Cycle: 8-12 weeks on, then 4 weeks off
Start: 100 mcg once daily at bedtime, fasted, about week 1
Then: 200 mcg weeks 2-3 (1x or split 2x)
Target: 200-300 mcg/day, 1-2x daily, weeks 4-8. Per-shot ceiling 100-300 mcg.
Cycle: 8-12 weeks on, then 4 weeks off
Kisspeptingrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 3 · trial / community
Clinical trialKisspeptin-10 in healthy men (George, JCEM 2011)
Single bolus or infusion
Start: IV bolus: maximal LH rise at 1 mcg/kg (3 mcg/kg gave a smaller response)
Then: None
Target: Infusions at 1.5 and 4 mcg/kg/h raised LH
Start: IV bolus: maximal LH rise at 1 mcg/kg (3 mcg/kg gave a smaller response)
Then: None
Target: Infusions at 1.5 and 4 mcg/kg/h raised LH
SourcePubMed 21632807 ↗
Clinical trialKisspeptin-54 IVF trigger (Abbara 2015)
Single dose
Start: Arms: 3.2, 6.4, 9.6 or 12.8 nmol/kg
Then: None
Target: Highest pregnancy rates at 9.6 nmol/kg
Start: Arms: 3.2, 6.4, 9.6 or 12.8 nmol/kg
Then: None
Target: Highest pregnancy rates at 9.6 nmol/kg
SourcePubMed 26192876 ↗
Community protocol — not clinically establishedCommunity guide (kisspeptin-10)
1-2x daily
Start: Low-dose pulse 50-100 mcg SC
Then: Standard pulse 100-200 mcg; or 100 mcg twice daily
Target: 50-200 mcg 1-2x daily
Cycle: Short 2-4 weeks on / 2-4 off; standard 4-6 weeks on / 4 off
Start: Low-dose pulse 50-100 mcg SC
Then: Standard pulse 100-200 mcg; or 100 mcg twice daily
Target: 50-200 mcg 1-2x daily
Cycle: Short 2-4 weeks on / 2-4 off; standard 4-6 weeks on / 4 off
KLOWgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily
Start: Weeks 1-2: about 1.25 mg GHK-Cu + about 250 mcg each of KPV, BPC-157, TB-500
Then: Weeks 3-4: about 2.5 mg GHK-Cu + about 500 mcg each of the other three. Weeks 5-8: about 3.75 mg GHK-Cu + about 750 mcg each.
Target: Titrated as above ("representative titration phases")
Cycle: 4-6 weeks on, 2-4 weeks off; copper accumulation from GHK-Cu drives the off period
Start: Weeks 1-2: about 1.25 mg GHK-Cu + about 250 mcg each of KPV, BPC-157, TB-500
Then: Weeks 3-4: about 2.5 mg GHK-Cu + about 500 mcg each of the other three. Weeks 5-8: about 3.75 mg GHK-Cu + about 750 mcg each.
Target: Titrated as above ("representative titration phases")
Cycle: 4-6 weeks on, 2-4 weeks off; copper accumulation from GHK-Cu drives the off period
KPVgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
SC often once daily; oral once or twice daily
Start: Not separately stated
Then: Not stated
Target: 200-500 mcg
Start: Not separately stated
Then: Not stated
Target: 200-500 mcg
LL-37grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trialVenous leg ulcers (Grönberg, Wound Repair Regen 2014)
Twice weekly, 4 weeks
Start: Arms: 0.5, 1.6 or 3.2 mg/mL
Then: None
Target: Best effect at 0.5 and 1.6 mg/mL; 3.2 mg/mL was less effective with more local reactions
Start: Arms: 0.5, 1.6 or 3.2 mg/mL
Then: None
Target: Best effect at 0.5 and 1.6 mg/mL; 3.2 mg/mL was less effective with more local reactions
Community protocol — not clinically establishedCommunity guide
Once daily, often 5 days/week
Start: 100-200 mcg/day SC
Then: Up to 500 mcg/day
Target: 100-500 mcg/day
Cycle: 2-4 weeks, then a break (length not stated)
Start: 100-200 mcg/day SC
Then: Up to 500 mcg/day
Target: 100-500 mcg/day
Cycle: 2-4 weeks, then a break (length not stated)
Melanotan IIgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 3 · trial / community
Clinical trialErectile dysfunction crossover (Wessells, J Urol 1998, n=10)
Single doses (crossover)
Start: 0.025 mg/kg SC
Then: None
Target: 0.025 mg/kg SC; erections in 8/10; "manageable side effects"
Start: 0.025 mg/kg SC
Then: None
Target: 0.025 mg/kg SC; erections in 8/10; "manageable side effects"
SourcePubMed 9679884 ↗
Clinical trialPilot phase 1 in 3 healthy men (Dorr, Life Sci 1996)
Alternate weekdays for 2 weeks
Start: 0.01 mg/kg
Then: 0.005 mg/kg steps
Target: 0.025-0.03 mg/kg
Start: 0.01 mg/kg
Then: 0.005 mg/kg steps
Target: 0.025-0.03 mg/kg
Sourcesuperpower.com summary ↗
Community protocol — not clinically establishedCommunity guide
Loading daily, then 1-2x weekly maintenance; bedtime
Start: Days 1-3: 100-250 mcg daily (tolerance test)
Then: Days 4-14: 250-500 mcg daily; weeks 3-6: 500-1,000 mcg daily until target pigmentation
Target: Maintenance 500-1,000 mcg 1-2x weekly; light maintenance 250-500 mcg 1x weekly or less
Cycle: Short 4 weeks loading + 4+ weeks off; standard 6 + 4-6 off; "Most protocols cap loading at 8 weeks"
Start: Days 1-3: 100-250 mcg daily (tolerance test)
Then: Days 4-14: 250-500 mcg daily; weeks 3-6: 500-1,000 mcg daily until target pigmentation
Target: Maintenance 500-1,000 mcg 1-2x weekly; light maintenance 250-500 mcg 1x weekly or less
Cycle: Short 4 weeks loading + 4+ weeks off; standard 6 + 4-6 off; "Most protocols cap loading at 8 weeks"
MGFgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Immediately post-workout
Start: 100-200 mcg IM post-workout
Then: Not stated
Target: 100-200 mcg IM
Cycle: 4-6 weeks on, 4-6 weeks off
Start: 100-200 mcg IM post-workout
Then: Not stated
Target: 100-200 mcg IM
Cycle: 4-6 weeks on, 4-6 weeks off
Sourcepeptidewiki.co ↗
MK-677grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial / community
Clinical trial2-year RCT in adults aged 60-81 (Nass, Ann Intern Med 2008)
Once daily, 2 years
Start: 25 mg once daily
Then: None
Target: 25 mg once daily
Start: 25 mg once daily
Then: None
Target: 25 mg once daily
SourcePubMed 18981485 ↗
Community protocol — not clinically establishedCommunity guide
Once daily, before bed
Start: Conservative 10-15 mg nightly
Then: Not a titration; three protocols instead
Target: Standard 25 mg nightly 12+ weeks; conservative 10-15 mg 8 weeks; low-dose long-term 10 mg up to 24 weeks
Cycle: 8-16 weeks standard; "cycling 8 on / 4 off" conservative
Start: Conservative 10-15 mg nightly
Then: Not a titration; three protocols instead
Target: Standard 25 mg nightly 12+ weeks; conservative 10-15 mg 8 weeks; low-dose long-term 10 mg up to 24 weeks
Cycle: 8-16 weeks standard; "cycling 8 on / 4 off" conservative
Sourcepathtopeptides.com ↗
MOTS-cgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
2-3 times per week
Start: 5 mg SC 2x per week
Then: No titration ladder. Tiers: lower 5 mg 2x/week for 4 weeks; standard 5 mg 3x/week for 4-6 weeks; higher 10 mg 2-3x/week for 6-8 weeks.
Target: 5-10 mg per injection
Cycle: 4-8 weeks on, then an equal time off
Start: 5 mg SC 2x per week
Then: No titration ladder. Tiers: lower 5 mg 2x/week for 4 weeks; standard 5 mg 3x/week for 4-6 weeks; higher 10 mg 2-3x/week for 6-8 weeks.
Target: 5-10 mg per injection
Cycle: 4-8 weeks on, then an equal time off
PEG-MGFgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
2-3x per week on training days, within 1-2 h post-workout
Start: 200 mcg, 2x/week (the source's "beginner")
Then: 300 mcg 2-3x/week ("intermediate"); 400 mcg 3x/week ("advanced")
Target: 200-400 mcg per injection, 2-3x/week
Cycle: 4-6 weeks on, 4-6 weeks off
Start: 200 mcg, 2x/week (the source's "beginner")
Then: 300 mcg 2-3x/week ("intermediate"); 400 mcg 3x/week ("advanced")
Target: 200-400 mcg per injection, 2-3x/week
Cycle: 4-6 weeks on, 4-6 weeks off
Sourcepeptidewiki.co ↗
Selankgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
SC once daily; intranasal split 2-3x daily
Start: SC 250-300 mcg once daily, weeks 1-2
Then: SC 400-500 mcg weeks 3-4 if tolerated
Target: SC 250-500 mcg daily. Intranasal 600-2,700 mcg/day split into 2-3 administrations.
Cycle: SC 4 weeks on / 4 weeks off. Intranasal 14-21 days with a 1-3 week washout.
Start: SC 250-300 mcg once daily, weeks 1-2
Then: SC 400-500 mcg weeks 3-4 if tolerated
Target: SC 250-500 mcg daily. Intranasal 600-2,700 mcg/day split into 2-3 administrations.
Cycle: SC 4 weeks on / 4 weeks off. Intranasal 14-21 days with a 1-3 week washout.
Semaxgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Intranasal typically 2x daily (morning + early afternoon)
Start: No formal titration ("beginning with lower ranges")
Then: None described
Target: Intranasal about 0.6-1.5 mg/day split morning + early afternoon. SC: "sub-milligram per administration".
Cycle: Short 10-14 days; extended 4-6 weeks; cycled 4-6 on / 2-4 off
Start: No formal titration ("beginning with lower ranges")
Then: None described
Target: Intranasal about 0.6-1.5 mg/day split morning + early afternoon. SC: "sub-milligram per administration".
Cycle: Short 10-14 days; extended 4-6 weeks; cycled 4-6 on / 2-4 off
Sermorelingrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · label / community
Label — former US label (Geref, withdrawn)Geref, pediatric GH deficiency (as summarised in review)
Once daily at bedtime
Start: 30 mcg/kg SC once daily at bedtime
Then: None
Target: 30 mcg/kg nightly, prepubertal children with idiopathic GH deficiency
Start: 30 mcg/kg SC once daily at bedtime
Then: None
Target: 30 mcg/kg nightly, prepubertal children with idiopathic GH deficiency
Community protocol — not clinically establishedCommunity guide
Nightly, 30-60 minutes before bed, on an empty stomach
Start: 100 mcg nightly, weeks 1-2
Then: 200 mcg weeks 3-4; 300 mcg weeks 5-8; 400-500 mcg week 9+ "if response at 300 mcg is not enough"
Target: 200-300 mcg nightly
Cycle: 3-6 months at target dose; some use 5 on / 2 off
Start: 100 mcg nightly, weeks 1-2
Then: 200 mcg weeks 3-4; 300 mcg weeks 5-8; 400-500 mcg week 9+ "if response at 300 mcg is not enough"
Target: 200-300 mcg nightly
Cycle: 3-6 months at target dose; some use 5 on / 2 off
TB-500grade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Twice weekly while loading, once weekly in maintenance
Start: Loading about 2-2.5 mg SC twice weekly, weeks 1-6
Then: No escalation; loading then step-down to maintenance
Target: Maintenance about 2-2.5 mg SC once weekly, weeks 7-12 or longer
Cycle: 8-12 weeks total, then 4-8 weeks off
Start: Loading about 2-2.5 mg SC twice weekly, weeks 1-6
Then: No escalation; loading then step-down to maintenance
Target: Maintenance about 2-2.5 mg SC once weekly, weeks 7-12 or longer
Cycle: 8-12 weeks total, then 4-8 weeks off
Thymosin Beta-4 (Tβ4)grade CNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 2 · trial
Clinical trialPhase 1 IV safety study (healthy volunteers)
Single dose, then daily for 14 days
Start: Single ascending doses: 42, 140, 420 or 1260 mg
Then: Same dose daily for 14 days
Target: Safety study only; no dose-limiting toxicity
Start: Single ascending doses: 42, 140, 420 or 1260 mg
Then: Same dose daily for 14 days
Target: Safety study only; no dose-limiting toxicity
SourcePubMed 20536472 ↗
Clinical trialRGN-259 eye drops (neurotrophic keratopathy / dry eye)
5 times/day (neurotrophic keratopathy); twice daily (dry eye)
Start: 0.1% RGN-259
Then: None
Target: 5 times/day for 4 weeks (NK, n=18); twice daily for 28 days (dry eye)
Start: 0.1% RGN-259
Then: None
Target: 5 times/day for 4 weeks (NK, n=18); twice daily for 28 days (dry eye)
Tri-Healgrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Once daily
Start: 10 units (0.10 mL) once daily at 3 mL reconstitution
Then: "Advanced" tier: 20 units (0.20 mL) daily
Target: 10-20 units daily
Cycle: 4-8 weeks then reassess
Start: 10 units (0.10 mL) once daily at 3 mL reconstitution
Then: "Advanced" tier: 20 units (0.20 mL) daily
Target: 10-20 units daily
Cycle: 4-8 weeks then reassess
Sourcedosagepeptide.com ↗
VIPgrade CNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 3 · trial / community
Clinical trialAviptadil (synthetic VIP) in COVID-19 respiratory failure
IV over 12 h on days 1-3; inhaled three times daily
Start: IV 50 pmol/kg/h
Then: IV 100, then 150 pmol/kg/h
Target: IV 150 pmol/kg/h by day 3. Inhaled: 100 mcg three times daily.
Start: IV 50 pmol/kg/h
Then: IV 100, then 150 pmol/kg/h
Target: IV 150 pmol/kg/h by day 3. Inhaled: 100 mcg three times daily.
Clinical trialIntranasal VIP in CIRS (open-label, uncontrolled)
Four times daily
Start: 50 mcg/spray
Then: None
Target: 50 mcg/spray, four times daily
Start: 50 mcg/spray
Then: None
Target: 50 mcg/spray, four times daily
Community protocol — not clinically establishedCommunity guide
SC 1-2x daily or 5x weekly; nasal 4-8 sprays/day
Start: SC 50 mcg once daily for 1-2 weeks ("conservative start")
Then: SC 100 mcg 1-2x daily ("standard"); 200 mcg 1-2x daily ("advanced")
Target: SC 50-200 mcg per injection; "100 mcg twice daily" most discussed. Nasal about 50 mcg/spray, 4-8 sprays/day.
Cycle: "Ongoing"; no cycle length given
Start: SC 50 mcg once daily for 1-2 weeks ("conservative start")
Then: SC 100 mcg 1-2x daily ("standard"); 200 mcg 1-2x daily ("advanced")
Target: SC 50-200 mcg per injection; "100 mcg twice daily" most discussed. Nasal about 50 mcg/spray, 4-8 sprays/day.
Cycle: "Ongoing"; no cycle length given
Wolverinegrade DNo human dose established.Nothing to cite
research-tier · no approval
research-tier · no approval
Protocols · 1 · community
Community protocol — not clinically establishedCommunity guide
Pre-blend: daily. Separate vials: BPC-157 daily + TB-500 twice weekly.
Start: Pre-blend: 1.0 mg total blend daily (500 mcg each)
Then: Not stated for the pre-blend. Separate-vial loading: BPC-157 250-500 mcg daily + TB-500 2.0-5.0 mg twice weekly.
Target: Separate-vial maintenance: BPC-157 250 mcg daily + TB-500 2.0 mg 1-2x/week
Cycle: 6-12 weeks total, often loading + maintenance
Start: Pre-blend: 1.0 mg total blend daily (500 mcg each)
Then: Not stated for the pre-blend. Separate-vial loading: BPC-157 250-500 mcg daily + TB-500 2.0-5.0 mg twice weekly.
Target: Separate-vial maintenance: BPC-157 250 mcg daily + TB-500 2.0 mg 1-2x/week
Cycle: 6-12 weeks total, often loading + maintenance
No body weight, no goals, no calculator: the same text for every reader. A figure without its source is indistinguishable from a recommendation, so every row and every protocol carries one. Community protocols are what guides and vendors publish, not what any trial established. Where nothing can be cited, the row says so.